Login Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

  • Watchlist

    Keep track of companies that you follow and research.

  • 10 Years of Data

    Full access to our data with predictions and indicators that we calculate daily.

  • Screener

    Full access to our screener with tons of custom values and customizable email notifications.

  • XLS Exports

    Excel export of financials and screeners you define and save.

Subscribe now
Screener Weekly Summary

Immunome, Inc. IMNM

Healthcare  —  Biotechnology
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)

Financial statements are limited to most recent four years or quarters for non-powerpack users

Ten years worth of data (where available), most important trends and XLS exports are available for our Powerpack users.

Register an account and get your Powerpack now or Login
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17
P/E ratio 0.00 0.00 0.00 — — — — — —
P/S ratio 149.04 68.88 15.59 — — — — — —
P/FCF ratio 0.00 0.00 0.00 — — — — — —
P/Operating CF (39.13) (14.81) (12.51) — — — — — —
P/B ratio 2.96 3.44 1.82 — — — — — —
Price to Tangible BV 2.96 3.44 1.82 — — — — — —
EV/Sales 97.16 44.88 5.75 — — — — — —
EV/EBITDA 0.00 0.00 0.00 — — — — — —
EV/Operating CF (6.41) (3.66) (10.66) — — — — — —
EV/FCF (6.10) (3.44) (9.60) — — — — — —
Quick Ratio 14.53 4.00 6.33 2.89 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Current Ratio 14.69 4.08 6.63 3.09 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Net Debt/EBITDA 2.92 0.71 1.26 0.56 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Debt/Assets 0.00% 0.00% 0.00% 0.26% ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡
Debt/Equity 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Asset Turnover 0.02 0.05 0.16 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ —
Operating CF/Net income 0.90 0.38 0.07 0.76 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Capex/Depreciation (83.49) 9.00 (3.85) (0.39) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Depreciation/Fixed assets 0.01 (0.08) 0.10 0.93 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Interest Coverage 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ —
ROE (52.09%) (194.63%) (156.45%) (115.73%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
ROA (46.00%) (150.71%) (123.77%) (91.54%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
ROIC 0.00% 0.00% 0.00% 0.00% ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Cash ROIC (15.96%) (30.34%) (3.74%) (79.30%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Return on Tangible Assets (33.69%) (165.38%) (85.48%) (234.50%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Accounts Receivable Turnover 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ — — —
Accounts Payable Turnover 0.00 0.00 0.00 0.23 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Inventory Turnover — — — 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ —
Average Days of Receivables 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ — — —
Average Days of Payables 0.00 0.00 0.00 1,388.27 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Days of Inventory on Hand — — — 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ —
Research and Development Expense of Revenue 2,554.19% 1,432.83% 164.71% 0.00% ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ —
Selling, General and Administrative Expense of Revenue 630.57% 364.51% 140.23% 0.00% ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ —
Intangible Assets out of Total Assets 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
Share Based Compensation of Revenue 370.12% 174.18% 44.39% 0.00% ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ —
Graham Net Nets 0.33 0.26 0.53 — — — — — —
Graham Number 0.00 0.00 0.00 — — — — — —
Earnings Yield (11.27%) (48.68%) (48.96%) — — — — — —
Free Cash Flow Yield (10.69%) (18.94%) (3.84%) — — — — — —
Revenue per Share 0.08 0.15 0.71 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ —
Operating CF per Share (2.19) (1.89) (0.38) (2.37) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Capex per Share (0.11) (0.12) (0.04) (0.02) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Free Cash Flow per Share (2.30) (2.01) (0.42) (2.39) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Cash per Share 7.48 3.71 6.96 1.68 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Shareholders Equity per Share 7.26 3.09 6.04 1.37 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Interest Debt per Share 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Book value per Share 7.26 3.09 6.04 1.37 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Free Cash Flow (200.60) (117.97) (8.40) (28.94) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Working Capital 615.79 167.03 122.87 15.32 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Capital Expenditures (9.68) (7.17) (0.83) (0.25) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Net Current Asset Value 611.93 162.26 116.05 15.26 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Average Receivables — — — 2.58 ‡‡‡‡‡ ‡‡‡‡‡ — — —
Average Payables 8.76 8.75 2.86 2.74 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Average Assets 461.71 194.39 86.29 40.99 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
Average Common Equity 407.75 150.52 68.27 32.42 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ —
EV/EBIT 0.00 0.00 0.00 — — — — — —
Capex to Sales 1.40 0.79 0.06 0.00 ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ —
Net Profit Margin (3,059.99%) (3,240.38%) (761.92%) 0.00% ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ —
Price to Operating Income 0.00 0.00 0.00 — — — — — —